Blood Cancers

A persistent, usually painless enlarged lymph node in the neck, armpit or groin; unexplained fever; drenching night sweats; weight loss; itching; fatigue; chest pressure; or abdominal swelling may occur. Infection is a much more common cause of enlarged nodes. Assessment is important when a node persists, enlarges, feels hard or is accompanied by systemic symptoms. Severe breathlessness, facial or neck swelling, confusion or rapidly worsening weakness requires urgent care.

Diagnosis requires adequate tissue. Excision of a lymph node often provides the best sample, while a carefully planned core biopsy may be suitable; fine-needle aspiration alone is frequently insufficient. Pathology combines morphology, immunohistochemistry, flow cytometry and sometimes cytogenetic or molecular tests. Blood tests and bone-marrow examination provide additional information but cannot replace lymph-node tissue in most cases. Expert haematopathology review is valuable because lymphoma includes many biologically different diseases.

Lymphoma is broadly divided into Hodgkin and non-Hodgkin lymphoma, with many B-cell, T-cell and NK-cell subtypes. Some are indolent and others aggressive; an aggressive label does not mean untreatable, and several aggressive lymphomas are highly curable. PET-CT or CT, examination, blood tests and selected bone-marrow assessment determine sites of disease. Stage describes distribution, but subtype, prognostic factors and treatment response can be more important than stage alone.

Treatment may include observation, antibody therapy, chemotherapy, targeted tablets, immunotherapy, radiotherapy, antibody-drug conjugates, cellular therapy or stem-cell transplantation. The exact regimen depends on subtype, stage, symptoms, tumour burden, biomarkers, age and health. Some early lymphomas need limited treatment; some widespread indolent lymphomas need no immediate therapy; aggressive lymphomas may require prompt combination treatment. Fertility, infection prevention and tumour-lysis risk should be addressed before treatment.

Lymphoma is generally not directly inherited. First-degree relatives may have a modestly higher statistical risk for some subtypes, but the absolute risk usually remains low and there is no effective routine blood test or scan for unaffected relatives. Genetic counselling may be appropriate for an unusual family cluster, childhood-onset cancers or features of an immune or inherited syndrome. Relatives should seek assessment for persistent symptoms rather than undergo repeated screening scans.

Fatigue, pallor, fever, repeated infections, easy bruising, nose or gum bleeding, pinpoint skin spots, bone pain, enlarged lymph nodes or abdominal fullness can occur. Some chronic leukaemias are found on a routine blood count before symptoms develop. These findings have many other causes. Fever with marked weakness, uncontrolled bleeding, breathlessness, confusion or neurological symptoms needs urgent assessment, particularly when a blood count is severely abnormal.

A complete blood count and blood film may show abnormal cells or low normal-cell counts. Bone-marrow aspiration and biopsy usually confirm the diagnosis and provide material for flow cytometry, chromosome analysis and molecular testing. These tests distinguish acute lymphoblastic, acute myeloid, chronic lymphocytic and chronic myeloid leukaemias and their subtypes. A normal total white-cell count does not exclude leukaemia because abnormal cells may remain in marrow or be balanced by low normal cells.

Usually not. Acute leukaemias are classified by genetic and molecular features, disease burden, organ involvement and response, rather than a conventional stage I--IV system. Chronic lymphocytic leukaemia uses clinical staging and risk markers, while chronic myeloid leukaemia is described by disease phase and molecular response. These systems help estimate risk and select treatment. The same white-cell count can have very different meaning in different leukaemias.

Most leukaemias are not inherited and relatives do not need routine blood counts solely because one family member is affected. Genetic evaluation may be considered when myeloid cancers cluster in a family, disease occurs unusually young, or there are lifelong low counts, immune problems, congenital features or multiple cancers. If a hereditary predisposition is suspected, testing is especially important before choosing a related stem-cell donor. Testing healthy relatives should be guided by genetics and transplant specialists.

Persistent bone or back pain, fractures, fatigue from anaemia, repeated infections, kidney problems, high calcium causing thirst or confusion, weight loss or numbness can occur. Some people first have a monoclonal protein without symptoms, called MGUS, which is not active myeloma. Sudden leg weakness, loss of bladder or bowel control, severe confusion, reduced urine or uncontrolled pain requires urgent care because spinal compression, high calcium or kidney injury may be present.

Testing may include blood counts, kidney function, calcium, serum protein electrophoresis, immunofixation and free light chains; urine studies may also be needed. Bone-marrow examination measures clonal plasma cells and provides chromosome or molecular risk information. Whole-body low-dose CT, PET-CT or MRI assesses bone lesions and marrow involvement. Diagnosis requires defined myeloma-related organ damage or specific high-risk biomarkers; an M-protein alone does not always mean treatment is needed.

Myeloma staging uses blood markers such as beta-2 microglobulin, albumin and LDH together with selected chromosome abnormalities. Doctors also assess kidney function, frailty, bone disease and eligibility for intensive treatment or transplant. Stage does not describe a single tumour mass, and bone lesions do not automatically mean a separate bone cancer. Response is measured using changes in monoclonal protein, free light chains, marrow findings and imaging when appropriate.

Myeloma and MGUS can cluster modestly in families, but most cases are not caused by an identifiable inherited syndrome. Routine electrophoresis, scans or bone-marrow tests are not recommended for healthy relatives outside a research or specialist context. Relatives with persistent anaemia, kidney dysfunction, high calcium or bone pain should be assessed on their own clinical merits. A strong family cluster of plasma-cell or other blood cancers can be discussed with a haematologist or genetics service.

Myelodysplastic syndromes, or MDS, are clonal bone-marrow cancers in which blood-cell production becomes ineffective and abnormal. Low red cells can cause fatigue and breathlessness; low neutrophils increase infection risk; low platelets cause bruising or bleeding. Some people are diagnosed from routine blood counts before symptoms. Many non-cancerous conditions also lower counts, so persistent cytopenias require careful evaluation rather than assuming MDS.

Doctors review the blood count, blood film, medicines, nutrition and other possible causes of low counts. Bone-marrow aspiration and biopsy assess cell appearance, cellularity and blast percentage. Chromosome and molecular tests help confirm clonality, classify disease and estimate risk. No single mutation automatically proves MDS because age-related clonal haematopoiesis can occur without it. Expert correlation of blood, marrow, genetics and clinical history is essential.

MDS is risk-stratified rather than assigned a conventional solid-tumour stage. Scoring systems combine blood counts, blast percentage and chromosome or molecular findings to estimate the likelihood of progression and guide treatment intensity. Lower-risk MDS may mainly cause chronic low counts, while higher-risk disease has a greater chance of evolving to acute myeloid leukaemia. Risk can change over time, so reassessment may be needed when counts or symptoms worsen.

Most MDS is acquired rather than inherited. Genetic counselling is more relevant with unusually young onset, several relatives with MDS or acute leukaemia, lifelong low platelets or other blood counts, pulmonary or liver disease, immune problems or characteristic physical findings. Identifying a germline predisposition can affect treatment and related-donor selection. Healthy relatives should not undergo broad testing without counselling because results can be uncertain and require specialised interpretation.

Leukaemia usually begins in blood-forming tissue and often involves marrow and blood. Lymphoma arises from lymphocytes and commonly forms disease in lymph nodes or organs, although it can also involve blood and marrow. Myeloma is a cancer of plasma cells, which normally make antibodies, and commonly affects marrow, bones, kidneys and immunity. These labels include many subtypes with different behaviour; the exact pathology matters more than the broad name.

Most are not directly inherited. A small proportion occur in the setting of a germline predisposition affecting DNA repair, immune function, telomeres or blood-cell development. Suspicion rises with young onset, multiple affected relatives, lifelong abnormal counts, unusual infections or physical features, or multiple cancers in one person. Genetic counselling should guide testing, especially before a related donor is chosen for stem-cell transplantation.

Yes. Lymphoma and myeloma may occur with a normal white-cell count, and some leukaemias initially remain mainly in bone marrow. A total count can also look normal while the proportions or types of cells are abnormal. Conversely, infection, steroids and many benign conditions can raise the white-cell count. Diagnosis relies on the pattern of symptoms, examination, blood film, tissue or marrow pathology, flow cytometry and genetic tests---not one number alone.

Flow cytometry analyses proteins on and inside individual cells from blood, marrow, lymph node or body fluid. The pattern helps identify abnormal B cells, T cells, plasma cells or immature myeloid cells and can rapidly distinguish some leukaemias and lymphomas. It complements, rather than replaces, microscopy and tissue architecture. It is also used in selected diseases to measure residual abnormal cells after treatment. The required sample and marker panel depend on the suspected diagnosis.

Cytogenetic tests examine chromosome number and structure using methods such as karyotyping or FISH. Molecular tests look for specific gene variants, fusions or broader mutation patterns using PCR or sequencing. Results can confirm a diagnosis, estimate risk, identify a targeted treatment and provide a marker for response. A genetic change found in cancer cells is not automatically inherited; germline testing usually requires a separate sample and appropriate counselling.

MRD testing looks for very small numbers of cancer cells that remain below the level seen with routine microscopy. Flow cytometry, PCR or sequencing may be used, depending on the disease. MRD can refine prognosis and guide treatment in selected leukaemias, myeloma and lymphomas, but thresholds and decisions are disease-specific. An MRD-positive result is not the same as immediate clinical relapse, and an MRD-negative result does not guarantee cure.

Stem-cell transplantation allows intensive treatment or replaces diseased blood formation with healthy donor stem cells. Before infusion, patients receive conditioning chemotherapy, sometimes with radiotherapy. The infused cells travel to the marrow and begin making blood cells. Transplant is a process, not an operation, and involves infection, bleeding, organ and long-term risks. Its value depends on disease risk, response, age, health, donor options and alternative therapies.

An autologous transplant uses the patient’s own previously collected stem cells, mainly to rescue marrow after high-dose chemotherapy. It does not create a donor immune effect. An allogeneic transplant uses stem cells from another person and can provide a graft-versus-cancer effect, but it adds risks such as graft-versus-host disease and prolonged immune suppression. The two procedures treat different diseases and are not interchangeable.

No. Many blood cancers are cured or controlled without transplant, and some patients would face more harm than benefit from it. Transplant is considered when it meaningfully improves the chance of cure or durable control compared with other options. Disease biology, remission status, MRD, previous treatment, age, organ function, frailty, donor availability and patient preferences all matter. A transplant-centre opinion can be useful without committing the patient to proceed.

Some indolent lymphomas can remain stable for years and early treatment has not been shown to improve survival when there are no symptoms, threatened organs or significant low counts. Active surveillance therefore avoids treatment toxicity while preserving later options. It includes planned visits, examination and selected tests; it is not neglect. Treatment begins if defined clinical criteria develop, such as symptoms, progressive bulky disease, organ risk or worsening blood counts.

Neutropenia means too few neutrophils, increasing infection risk. Thrombocytopenia means too few platelets, increasing bruising and bleeding risk. The seriousness depends on the count, how rapidly it fell, symptoms, cause and other medicines---not the number alone. Patients should avoid self-starting antibiotics or stopping prescribed treatment without advice. Fever with neutropenia and significant bleeding with thrombocytopenia can be life-threatening emergencies.

Seek urgent assessment for a temperature of 38°C or above during anticancer treatment, chills with weakness, breathing difficulty, chest pain, fainting, confusion, uncontrolled bleeding, black stools, vomiting blood, severe headache or new neurological symptoms. Do not wait for the next clinic visit. The oncology team may set individual thresholds based on treatment and counts. Bring the treatment record and state immediately that the patient has a blood cancer or is receiving anticancer therapy.

Transplant restores blood-forming stem cells after intensive treatment or replaces an abnormal immune and marrow system with donor cells. It is used only for selected blood cancers and a few other conditions after careful risk assessment.

Conditioning is chemotherapy, sometimes with radiotherapy, given before the stem-cell infusion. It reduces cancer or abnormal marrow cells, suppresses the immune system and creates space for the new cells. Intensity is tailored to disease, age and fitness.

Engraftment occurs when infused stem cells begin producing new blood cells. Counts are monitored closely; infection, bleeding and transfusion risks are highest before adequate recovery.

GVHD occurs after allogeneic transplant when donor immune cells attack the patient’s tissues. It may affect skin, gut, liver, mouth, eyes, lungs or other organs and can be acute or chronic. New rash, diarrhoea, jaundice, breathlessness or severe dryness must be reported promptly.

CAR T therapy collects a patient’s T cells, genetically modifies them to recognise a cancer target, expands them and returns them by infusion. It is used for selected blood cancers and is available only through specialised programmes.

Manufacturing commonly takes several weeks. Some patients need bridging treatment to control disease, followed by lymphodepleting chemotherapy shortly before the CAR T infusion. Plans vary by product and disease urgency.

CRS is an inflammatory reaction after CAR T therapy that may cause fever, low blood pressure, low oxygen or organ dysfunction. It can become life-threatening and requires immediate assessment in a trained centre; effective treatments are available.

Patients may develop confusion, difficulty speaking or writing, tremor, severe drowsiness, agitation, weakness or seizures. These symptoms require urgent specialist assessment and should never be watched at home without contacting the CAR T team.

Follow-up includes blood counts, infection prevention, vaccination planning, organ monitoring, disease-response assessment and management of immune complications. Patients may need to remain near the treating centre and have a full-time caregiver for a specified period.